Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery

NCT ID: NCT02009033

Last Updated: 2013-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect of thin fluid with starch versus thin fluid without starch on coagulation in elective surgery when the patient is normovolæmic during operation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary goal is to register coagulation on basis of blood samples inclusive thromboelastography results.

The secondary goal is to register blood loss and use of blood products during operation.

The trial concerns 40 patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Disorders of Coagulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ringer's lactate

Fluid therapy during operation

Group Type EXPERIMENTAL

Lactated Ringer

Intervention Type DRUG

When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.

Hydroxyethylstarch

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactated Ringer

When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.

Intervention Type DRUG

Hydroxyethylstarch

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient older than 18 years.
* Indication for elective surgery with removal of the urine bladder.
* Patient without anticoagulative, acethylsalisylsyre or NSAID medicine during the last 5 days,if using.

Exclusion Criteria

* Cerebral haemorrhage
* Renal insufficiency demanding dialysis
* Manifest cardiac and hepatic insufficiency
* Disturbance in coagulation
* Hypernatriæmi
* Hyperchloræmi
* Pregnant or nursing
* Allergic to hydroxyethylstarch
* Participating in another trial-if interferring the present trial
* Incapable of managing his own affairs.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

K. C. Rasmussen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

K. C. Rasmussen

MD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Niels Henry Secher, Professor

Role: STUDY_CHAIR

Rigshospitalet , Dept. 2042, 2100 Copenhagen

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-2-2011-063

Identifier Type: -

Identifier Source: org_study_id